Mendel Capital Management LLC Has $1.48 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Mendel Capital Management LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 4,602 shares of the medical research company’s stock after purchasing an additional 45 shares during the quarter. Amgen accounts for approximately 0.9% of Mendel Capital Management LLC’s investment portfolio, making the stock its 25th biggest holding. Mendel Capital Management LLC’s holdings in Amgen were worth $1,483,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hillsdale Investment Management Inc. grew its position in Amgen by 44.3% in the 1st quarter. Hillsdale Investment Management Inc. now owns 1,400 shares of the medical research company’s stock valued at $398,000 after purchasing an additional 430 shares during the period. PYA Waltman Capital LLC increased its position in shares of Amgen by 16.4% during the first quarter. PYA Waltman Capital LLC now owns 9,541 shares of the medical research company’s stock worth $2,713,000 after acquiring an additional 1,347 shares in the last quarter. Bessemer Group Inc. lifted its position in Amgen by 29.3% in the 1st quarter. Bessemer Group Inc. now owns 37,202 shares of the medical research company’s stock valued at $10,578,000 after acquiring an additional 8,441 shares in the last quarter. Arjuna Capital increased its holdings in Amgen by 58.3% during the 1st quarter. Arjuna Capital now owns 24,142 shares of the medical research company’s stock worth $6,864,000 after purchasing an additional 8,893 shares in the last quarter. Finally, Lake Street Advisors Group LLC lifted its holdings in shares of Amgen by 240.8% in the first quarter. Lake Street Advisors Group LLC now owns 12,755 shares of the medical research company’s stock valued at $3,626,000 after purchasing an additional 9,012 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and set a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th. Wolfe Research initiated coverage on Amgen in a report on Friday. They set a “peer perform” rating for the company. Robert W. Baird restated an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Trading Down 4.2 %

Shares of AMGN stock opened at $283.61 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market cap of $152.45 billion, a P/E ratio of 36.31, a price-to-earnings-growth ratio of 2.53 and a beta of 0.60. The business has a 50-day moving average price of $320.85 and a two-hundred day moving average price of $318.65. Amgen Inc. has a 12-month low of $260.52 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the business earned $4.96 earnings per share. Equities analysts anticipate that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.17%. Amgen’s payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.